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Introduction: Young people with psychosis are six times more likely to be tobacco
smokers than their gender- and age-matched peers. Smoking is a major contributor
to the 15-year reduced life expectancy among people experiencing severe mental illness
(SMI). There is a lack of evidence-supported interventions for smoking cessation among
young people with SMI.
Material and Methods: The study comprised two phases and aimed to assess (i)
the prevalence of smoking among a community sample of young people with psychotic
illness or at high risk of developing psychosis; (ii) the proportion who engaged in the
intervention; (iii) the proportion who achieved smoking cessation; and (iv) secondary
smoking-related outcomes. In phase one, prevalence of smoking was assessed among
young people with psychotic illness or at high risk of developing psychosis attending
a community-based youth mental health service between 16/5/2017 and 16/11/2017.
In phase two, over a 1-year period, individuals identified as smokers were invited to
participate in a 12-week tailored smoking cessation intervention program that included
pharmacological treatment, motivational interviewing, and behavioral change techniques.
Those unwilling to participate in a full intervention were offered a brief intervention.
Participants of the full intervention were assessed at baseline and at week 12 endpoint
on: daily cigarettes smoked (self-report), exhaled CO, nicotine dependence, readiness to
quit, and confidence to quit.
Results: In phase one, smoking prevalence was 48.2% (53 of 110) among clients
of the youth mental health service. Smokers were significantly more likely to be male
(X2 = 6.41 p = 0.009). During phase two, 41 of 61 eligible clients engaged in a smoking
cessation intervention (67.2%). Effectiveness: twenty-one clients participated in a full
intervention (34.4%), of whom three (14.3%) received a brief intervention initially and
during engagement converted to full intervention. Twenty participants (32.8%) received
a brief intervention only. Ten participants in the full intervention (47.6%) and five in the
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brief intervention (25%) dropped out. Six (28.6% of full intervention) reported smoking
cessation verified by CO monitoring. Participants who completed the full intervention
(n = 9) reduced number of cigarettes smoked, nicotine dependence, and exhaled
CO, while readiness to quit and confidence to quit increased. Pharmacotherapy was
predominantly combination NRT (n = 18; 85.7%), varenicline (4.8%), oral NRT only
(4.8%), or none (4.8%). No adverse events were reported.
Conclusion: This pilot real-world study demonstrates that both screening for smoking
and offering an effective smoking cessation intervention are achievable in youth
experiencing or at risk of psychosis.
Keywords: smoking, tobacco, youth, adolescent, psychosis, first episode psychosis, at-risk for psychosis,
intervention
INTRODUCTION
Among people experiencing severe mental illness (SMI), tobacco
smoking is a modifiable risk factor for poor physical and mental
health and thus a key priority for intervention. Approximately
two thirds of people who experience psychotic illness smoke
(1, 2). Very high smoking rates (59%) are also observed among
individuals experiencing first episode psychosis (FEP), a rate six
times that observed in age-matched peers (3). Individuals at high
risk for the development of psychosis have higher tobacco use
than healthy controls (4). Regular tobacco use is initiated on
average (mean) 5.3 years prior to psychosis onset (3). A possible
causal link between psychosis and tobacco smoking is suggested
by a large meta-analysis which found overall relative risk of new
onset psychotic disorders to be double that in tobacco smokers
compared to non-smokers (5).
These findings suggest that daily tobacco use is associated
with both increased risk for and earlier onset of psychotic illness
and are thus highly relevant to populations with established FEP
and those at high risk of developing psychotic illness. Within
these populations, smoking among youth is a key consideration
given that adolescence (12–17 years) and young adulthood (18–
24 years) are critical periods in which smoking behaviors are
established (6). The first cigarette is often smoked in adolescence,
with tobacco experimentation generally developing into nicotine
dependence before age 25 (6). Both young age and poor mental
health are associated with higher levels of nicotine addiction
which contribute to and sustain high smoking rates (7).
The benefits for smoking cessation and reduction in people
experiencing SMI are clear, including a lowering of risk for
cardiovascular and respiratory diseases and cancer—all of which
are implicated in the known 10–20 year life expectancy gap (8–
10). Further, smoking cessation/reduction demonstrably lowers
stress levels, alleviates the financial burden associated with
sustained nicotine addiction, and decreases the need for high-
dose psychotropic medication, consequently lessening adverse
side effects (11). Finally, long-term cessation may lead to direct
clinical improvements in mental health, with improvements in
anxiety and depression at levels of effect equal to or greater
than those of antidepressant medication for anxiety and mood
disorders (12).
Nonetheless, despite significant reductions in smoking rates
among general adult populations over the past two decades, the
very high smoking rates among people experiencing psychotic
illness have remained almost unchanged (2, 13). It would be
erroneous, however, to conclude that this reflects that people
with mental health issues do not wish to stop smoking. Evidence
suggests otherwise: most individuals questioned—in both mental
health inpatient and community health settings—express a desire
to quit (14–17) and welcome help to do so (18). Among people
experiencing psychosis, 73% have attempted to quit smoking
(2). Indeed, people with mental health disorders have similar or
higher levels of motivation to quit when compared to the general
population (19). Importantly, individuals with SMI, including
young people with FEP, have poorer health literacy than healthy
controls but, when shown smoking-related health warnings, they
perceive them as effective (20). Nonetheless, individuals with SMI
make fewer quit attempts and successful quit rates remain low
(21, 22).
Understanding why individuals experiencing SMI are more
likely to fail quitting is important as this will inform interventions
aimed at overcoming the barriers to quit. It has been suggested
that individuals experiencing SMI find quitting more difficult
than do other smokers because of a range of factors including
socioeconomic disadvantage, lack of familial and/or peer
abstinence support and cognitive deficits (23, 24). Standard
population cessation advice, which typically involves planning
a quit strategy and setting a quit date, may be too cognitive
an approach in some individuals with SMI, and indeed may
prove counterproductive by increasing anxiety, self-stigma, and
ideas of failure (25). Nonetheless, a review of smoking cessation
interventions in SMI found behavioral and pharmacological
interventions to be of similar effectiveness in smokers with
or without SMI (26). It is unclear, however, whether these
interventions would be effective in real-world settings, or be
generalizable to all SMI populations, as the people with SMI
who took part in those trials may have had better psychosocial
function than the general SMI population (24).
Alternative interventions may be needed which are tailored to
individuals experiencing SMI, or strategies employed to support
their progress through cessation attempts. Intensive tailored
support, provision of cessation medication, and access to peer
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support have each been highlighted as important elements for
successful interventions (7, 27). Among youth withmental health
issues, it has been suggested that cigarette smoking may act as a
tool for socialization and acceptance, which should be taken into
account when designing smoking cessation interventions (19).
In fact, little is known about what interventions will be effective
among youth smokers experiencing SMI. Among youth smokers
in the general population, smoking prevalence is successfully
impacted by adult-directed population-based strategies such as
cigarette price increases and implementation of clean indoor air
policies (28).
A recent smoking cessation trial demonstrated the feasibility
of offering tailored smoking cessation interventions to adult
individuals experiencing SMI. The intervention—comprising
behavioral support and pharmacotherapy delivered by a specialist
mental health nurse with tobacco cessation training—increased
engagement with services and sustained abstinence at rates
almost 3 times higher than usual care (29). Interventions such as
these are yet to be trialed in youth SMI populations. The present
study (y-QUIT) involved an individualized 12-week smoking
cessation intervention in youth experiencing psychotic illness or
at high risk of developing psychosis. The aims of the study were:
1. to measure the prevalence of self-reported smoking among a
community sample of young people with FEP or at high risk
of developing psychotic illness
2. to assess the proportion of individuals who engaged in the
intervention
3. to assess the proportion of individuals who achieved smoking
cessation, and
4. to assess secondary smoking-related outcomes.
MATERIALS AND METHODS
Setting
This study was undertaken as part of the y-QUIT program,
a local health district-funded project based in specialist early
intervention in psychosis, community youth mental health
(YMH) services in the South Eastern Sydney Local Health
District, Sydney Australia. These comprised all YMH services
across the three community mental health sites of the catchment
area. The YMH services offer care to young people who have
experienced first episode psychosis (FEP) or are deemed to
be at ultra-high risk for development of psychosis. Inclusion
criteria are age at presentation between 14 and 25 years inclusive.
A 2-year program of care is offered with some individuals
remaining with the service for a longer period. Ethics approval
was granted by the Prince of Wales Hospital Human Research
Ethics Committee [HREC ref no: 17/031 (LNR/17/POWH/50)].
Procedures
Screening and Prevalence [Phase One]
Cross-sectional smoking prevalence and eligibility for the y-
QUIT program was determined by administration of the
Brief Assessment for Tobacco Use (Appendix 1) The Brief
Assessment for Tobacco Use tool includes questions about
past and current smoking (including tailor made cigarettes,
roll your own, cannabis mixed with tobacco, cigars, chop
chop, or waterpipe/hubbly bubbly). All clients who answered
affirmatively to smoking anything in the past 30 days were
identified as smokers. The screening tool was administered
by the individual’s caseworker or other treating clinician, the
tobacco treatment specialist (BM) or the researcher-medical
student (CZ). Screening was conducted either in person or by
phone. Cross-sectional smoking prevalence was evaluated among
all individuals who were clients of the YMH services between
16/5/2017 and 16/11/2017.
Identification of Eligible Participants to Engage in an
Intervention [Phase Two]
All individuals who were clients of the YMH service between
16/5/2017 and 16/11/2017 [Phase One] who were identified as
smokers through screening were approached to engage in the
intervention. In addition, any young people newly joining the
YMH services between 17/11/2017 and 15/5/2018 who were
identified as smokers were approached to engage in intervention.
All smokers were offered a full intervention. Those unwilling to
participate in a full intervention were offered a brief intervention.
Clients who denied ever smoking, or smoking in the past 12
months, were deemed ineligible.
Measures [Phase Two]
1. Assessment of daily cigarettes smoked by self-report.
2. Exhaled carbon monoxide (CO) measured using a Bedfont
Micro Smokerlyzer (Air-met Scientific).
3. Nicotine dependence, assessed using the Heaviness of
Smoking Index (HSI) (30). The HSI was developed as a test
to measure nicotine dependence by using two questions from
the Fagerstrom Test for Nicotine Dependence: time to first
smoking in the morning and number of cigarettes per day. It
uses a six-point scale calculated from the number of cigarettes
smoked per day (1–10, 11–20, 21–30, 31+) and the time to
first cigarette after waking (less than/equal to 5, 6–30, 31–60,
and 61+ minutes). Nicotine dependence is then categorized
into a three-category variable: low (0–1), medium (2–4), and
high (5–6).
4. Readiness to quit by self-report (scale ranging 1–10:1 = low
readiness; 10= high readiness) (31)
5. Confidence to quit by self-report (scale ranging 1–10:1 = low
confidence; 10= high confidence) (31)
Scores on these measures were recorded by the y-QUIT tobacco
treatment specialist throughout interventions on the Smoking
Monitoring Form (available on request). The proportion of
smokers who engaged in full and/or brief interventions was
recorded by the tobacco treatment specialist. Smoking cessation
by self-report was confirmed by biochemically verified CO breath
test.
Interventions [Phase Two]
All interventions were delivered by the y-QUIT tobacco
treatment specialist, a mental health nurse with additional
tobacco cessation training. The tobacco treatment specialist
worked closely with the multi-disciplinary YMH teams and was
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embedded within the Keeping the Body in Mind program which
provides lifestyle interventions for these young people (32).
Full intervention
The intensive tobacco dependence intervention comprised an
individualized 12-week program incorporating motivational
interviewing, counseling support and pharmacological agents.
Intensive tobacco dependence intervention involves the delivery
of sessions over the phone or face to face that last longer than
10min, with a minimum of 4 sessions. Duration of face to
face appointments was typically 1 h for the first, and 30min
for subsequent sessions. Pharmacological interventions including
nicotine replacement therapy (NRT) as transdermal patches, oral
gum, nicotine inhaler or a combination, and varenicline, were
discussed with the participant and where appropriate prescribed.
NRT and prescribed smoking cessation treatments were provided
as part of the y-QUIT program to participants at no cost (NRT)
or cost only of prescription (varenicline). Ongoing support was
provided throughout (face-to-face and by phone) and there was
regular monitoring of mental state changes and adverse side
effects through clinical assessment by the treatment specialist
in conjunction with the clinical team. Psychotropic medications
were monitored, and doses adjusted by the treating psychiatrist
as required. At baseline and at 4-weekly intervals thereafter
terminating at week 12, participants completed the following
smoking-related measures: daily cigarettes smoked, exhaled CO,
nicotine dependence, readiness to quit, and confidence to quit.
Brief intervention
Brief interventions typically comprised 1–2 sessions delivered
face to face or by telephone. The goal of a brief intervention
was to initiate change in behavior, utilizing the 5A’s model
(33). A person’s smoking risk level was assessed using a
validated CO monitor. Motivational interviewing, counseling,
and measurement of exhaled CO were used to engage the
individual in a discussion about readiness to change smoking
behavior. Pharmacotherapy was available as NRT. Participants
were encouraged to convert to the full intervention. Harm
reduction strategies were offered to those who chose to continue
to smoke.
Outcomes [Phase Two]
The primary outcome was smoking cessation by self-report at
12-week endpoint in the full intervention with confirmation
of abstinence by exhaled CO measure of ≤4 ppm. Secondary
outcomes (number of cigarettes smoked per day; exhaled CO;
nicotine dependence; readiness to quit; confidence to quit) and
pharmacotherapy used were recorded at 12-week endpoint for all
those who completed the full intervention.
Statistical Analysis
Statistical analyses were conducted with IBM SPSS Statistics
Version 24 (IBM Corp 2016). For continuous variables, means
and standard deviations (SD) ormedians and interquartile ranges
were calculated. For tests of linear trend for categorical variables
chi square was calculated. Secondary smoking-related outcomes
were analyzed descriptively using mean (SD) or median (range).
TABLE 1 | Comparison of demographic characteristics between smokers and






Male (n) 41 31 X2 = 6.41
p = 0.009
Female (n) 12 26
Age (median,
range)
21 (18–27) 22 (16–26) t = 0.309
p = 0.76
Age (mean, SD) 21.3 (2.3) 21.5 (2.3)
RESULTS
Prevalence of Smoking [Phase One]
The prevalence of self-reported smoking among young people
with FEP or at high risk of developing psychotic illness was 48.2%
(53 of 110). Smokers were significantly more likely to be male
(X2 = 6.41 p= 0.009; Table 1).
Engagement: Proportion of Individuals
Who Engaged in an Intervention [Phase
Two]
During Phase Two, of the 61 clients offered y-QUIT, 41 engaged
in a smoking cessation intervention (67.2%). Twenty-one clients
participated in a full intervention (34.4%), of whom three (14.3%)
received a brief intervention initially and during engagement
converted to full intervention. The mean number of sessions
for full intervention was 5.1 (SD = 3.4; median = 6 (range
15). Twenty participants (32.8%) received a brief intervention
only. Sixteen individuals (26.2%) declined participation in any
intervention, and a further four clients (6.6%) were unable to
participate due to discharge from the service. The vast majority
of the individuals who participated in the full (90.5%), and
brief intervention (80.0%), were male (Table 2). Mean ages were
22.1 (2.0) and 20.6 (2.0) years, respectively. Ten participants in
the full intervention (47.6%) dropped out and two (9.6%) were
discharged from the YMH service before completion.
Effectiveness: Proportion of Individuals
Who Achieved Smoking Cessation [Phase
Two]
Six individuals (28.6% of full intervention; 14.6% of all
interventions) reported smoking cessation (verified by CO
monitoring) at completion of the full intervention (Table 2).
Effectiveness: Secondary
Smoking-Related Outcomes [Phase Two]
A further 3 participants (14.3% of full intervention) completed
the full intervention and reduced the number of cigarettes
smoked each day. As a group, participants who completed
the full intervention (n = 9) reduced number of cigarettes
smoked, nicotine dependence, and exhaled CO (Table 3). Both
readiness to quit and confidence to quit increased (Table 3).
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TABLE 2 | Demographic characteristics, quit prevalence, and pharmacotherapy












22 (19–25) 20 (18–25) 21 (18–25)
Age (mean, SD) 22.1 (2.0) 20.6 (2.0) 21.3 (2.1)
GENDER
Male (n) 19 16 35
Female (n) 2 4 6
Quit smoking (n,
%)
6 (28.6) 0 6 (14.6)
PHARMACOTHERAPY (n, %)
Oral NRT only 1 (4.8) 2 (10.0) 3 (7.3)
Combination NRT 18 (85.7) 4 (20.0) 22 (53.7)
Varenicline 1 (4.8) – 1 (2.4)
None 1 (4.8) 14 (70.0) 15 (36.6)
Pharmacotherapy in the full intervention was predominantly
combination NRT (n = 18; 85.7%), with one client each
prescribed varenicline (4.8%), oral NRT only (4.8%) or no
pharmacotherapy (4.8%; Table 2). No adverse events were
reported.
DISCUSSION
y-QUIT Smoking Cessation Intervention
To our knowledge, the engagement of youth with severe
mental illness and the effectiveness of tailored smoking cessation
interventions in this population have never previously been
reported. This real-world study demonstrated that the delivery
of an individualized smoking cessation intervention is both
achievable and effective in a community youth mental health
service.
Smoking Prevalence Among Youth With SMI
The prevalence of self-reported smoking of 48.2% was somewhat
lower than typical rates found in general SMI populations,
but is consistent with the estimated prevalence rate of 59% in
individuals with FEP (3). Smokers were significantly more likely
to be male, even accounting for the greater proportion of males
making up this population of FEP and at-risk for psychosis, in
this younger-age demographic (≤25 years at presentation).
Engagement With Intervention
Uptake rates of 67.2% in either a full or brief smoking cessation
intervention in this sample confirm that youth with SMI have
an interest in quitting tobacco smoking. Indeed, just over
a quarter of YMH service clients declined participation in
either intervention. Despite this high interest however, the full
intervention was engaged in by just over half of these individuals.
Of note, three individuals initially offered a brief intervention
converted to the full intervention once engaged. One further
young person offered brief intervention was discharged from
the YMH service before completing the brief intervention as
he had elected to trial an inpatient rehabilitation for comorbid
cannabis use. He subsequently reported that he had quit both
tobacco and cannabis. While this quit was not included in the
numbers reported here, it is evidence of another positive impact
of the y-QUIT program on smoking behavior in young people.
This provides support for offering a brief intervention in order
to provide a gateway to sustaining interest in and garnering
commitment to engagement in a full intervention. A notable
proportion of individuals dropped out: almost half of those
who initiated a full intervention. Some individuals who initially
declined engaging with the full intervention or who dropped
out became engaged or re-engaged with the tobacco treatment
specialist after the study period had completed. Previous studies
investigating smoking cessation interventions in people with SMI
have similarly noted high dropout rates and that both smoking
cessation and smoking reduction are more likely among those
individuals who engage fully with the intervention (34). This is
consistent with knowledge that tobacco dependence is a chronic
condition and that repeated attempts are typically required to
stop smoking successfully (29, 35).
Successful Quitting
Approximately one third of individuals who participated in the
full intervention reported smoking cessation at the 12-week
endpoint. This is a highly encouraging outcome and suggests
that this intervention is effective in youth with SMI, at least
in the short-term. Nonetheless, two-thirds of participants were
unsuccessful in quitting. This, together with the high drop-out
rates, also raises the question whether current evidence and/or
service user feedback might enhance the current approach to
make the interventions more acceptable. Future interventions
may need to incorporate recognition of these factors as obstacles
to quitting, and perhaps discuss strategies of harm minimization
(smoking reduction, use of NRT) as an initial alternative goal to
quitting.
Secondary Smoking-Related Outcomes
All participants who completed the full intervention reduced
daily number of cigarettes smoked, nicotine dependence, and
exhaled CO. This is important particularly in the youth
population, where there is evidence of a dose-response
relationship between increased number of cigarettes smoked
and risk for psychosis (36–38). In a large 15-year follow-up
study of psychosis risk and its relationship to tobacco use in
adolescence, smoking 10 or more cigarettes daily was associated
with a significantly increased risk for psychosis compared to
not smoking, while light smoking (1–9 cigarettes daily) was
not (38). This provides an additional argument to support
harm minimization of smoking in youth with SMI, and, if
tobacco smoking were causal in increasing psychosis risk, is
particularly relevant to those at high-risk for psychosis. Young
people reported increased readiness and confidence to quit on
completion of the full intervention.While both measures showed
a range of scores across participants, baseline scores were high
in the majority. This concords with previous evidence that
smokers with SMI have the desire to quit, but may require
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TABLE 3 | Smoking-related measures at baseline in clients who received the full intervention (n = 21), and at baseline and 12-week endpoint in those who completed the
full intervention (n = 9).
Baseline (n = 21) Baseline (completers; n = 9) Endpoint (completers; n = 9)
Number of cigarettes (mean, SD) 15.3 (9.8) 14.2 (11.8) 1.1 (1.9)
Number of cigarettes (median, IQR) 12.5 (0–35) 12.5 (0–35) 0 (0–6)
Heaviness smoking index (median, IQR) 3 (0–6) 3 (0–5) 0 (0–3)
Exhaled carbon monoxide (ppm; mean, SD) 15.8 (7.2) 14.8 (7.7) 5.9 (7.3)
Exhaled carbon monoxide (ppm; median, IQR) 16 (3–28) 15 (3–24) 3 (2–25)
Readiness to quit score (median, IQR) 7 (1–10) 7 (3–10) 10 (3–10)
Confidence to quit score (median, IQR) 7 (1–10) 7 (6–10) 10 (4–10)
additional assistance in order to successfully do so (19). Finally,
pharmacotherapy used was predominantly combination NRT
but a range of approaches—including use of varenicline or
alternatively use of no pharmaceutical agent—was applied, in
keeping with the focus on individualized care.
Limitations of y-QUIT
The present study presents preliminary 12-week outcomes only
and cannot speak to long-term effectiveness of this intervention.
Previous smoking cessation studies including the SCIMITAR
trial in SMI adults have assessed smoking cessation at 1 year
following randomization to intervention (29). Screening for
smoking status was only conducted routinely during Phase One,
that is, the first 6 months of the 12-month program. During
the latter 6 months, an additional eight young people who were
identified as smokers were offered the program. It is, however,
possible that among all young people newly entering the YMH
services in that 6-month period there may have been additional
smokers who were not identified in the absence of screening.
Lastly, brief interventions did not routinely assess smoking-
related measures or include follow-up evaluation to assess their
effectiveness in increasing desire, confidence, and readiness
to quit. This is an important area for future development,
particularly given the potential that brief interventions act as
segue into full interventions.
Implications of y-QUIT for Future
Interventions
Internationally, there is growing recognition of the need to
integrate smoking cessation into the treatment of people
experiencing SMI and the need to adapt programs developed
in the general population to address the specific needs of
people living with mental illness (24, 39). There remains
an overwhelming need for smoking to be addressed more
adequately in mental health services. A combination of culture
change, increased accessibility to intervention programs (both
pharmacological and non-pharmacological), and staff training
are necessary to address the life expectancy gap and inequality
experienced by youth with SMI. Future studies which include
varenicline as part of a routine intervention should also be
considered and may increase the quit rates, given recent evidence
indicating the efficacy and relative safety of this treatment in SMI
populations (40).
y-QUIT incorporated all elements recommended as necessary
to reduce the very high rates of smoking amongst this
population, namely training in brief interventions, motivational
interviewing, and pharmacological support (41). That delivery of
all interventions was by a mental health nurse with additional
tobacco cessation training demonstrates that this model is
immediately translatable to community mental health settings
where there is sufficient funding and support from clinicians and
managers to do so.
Conclusion
Smokers experiencing SMI are a priority target group for
smoking cessation interventions. The need to provide smoking
cessation to youth with SMI is all the more urgent, as successful
quitting at as early a stage as possible will optimally reduce
risk for smoking-related disease and life expectancy shortening.
This first-of-its-kind real-world smoking cessation program
demonstrates that both screening for smoking and offering
an effective smoking cessation intervention is acceptable and
effective in youth mental health services. Individuals with SMI
should be asked about smoking and should be provided with
smoking cessation interventions. The very high rates of tobacco
smoking in this population, and the failure of public health
measures to have had significant impact demand further urgent
work in tailoring interventions effective in this priority group.
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